National Institute of Allergy and Infectious Diseases	Document Number: DAIDS-OPC-A15-GUD- 00006	Revision Number: 02
Division of AIDS	Effective Date: 29 May 2024	Page: 1 of 14
Document Title: Appendix B Electronic Information System Evaluation	on Checklist	

Instructions:

- This checklist outlines the minimum requirements for an electronic information system. This checklist must be completed for each electronic information system used in the conduct of NIAID DAIDS Network studies conducted within the Clinical Trials Networks, unless otherwise specified in a formal agreement. Electronic information systems which fall under the scope of this checklist include systems from which clinical trial data (including 3rd Party data) may be submitted to the FDA, EMA or any other regulatory authorities or systems that collect, manage, store, or generate data that can be used to reconstruct a clinical trial.
 - Examples of systems that would require this checklist are electronic data capture systems, clinical trial management systems, electronic trial master file systems, safety systems, etc.
 - Examples of systems that would typically be excluded from this checklist are office desktop apps such as Word, Excel spreadsheets, Outlook, Teams, etc.
- This checklist should be completed by the entity that owns/implements the system. It is recommended that the CRS Leader, Investigators of Record, or Site PI as applicable are made aware that the site staff/IT personnel are performing this EIS Evaluation prior to completion and submission. Please utilize available reference resources including the Electronic Information Systems Policy and Appendix A, Requirements for using Electronic Information Systems in Clinical Research for additional information.
- This checklist must be completed for all new electronic information systems and for all subsequent software release versions of the system. To remain compliant there must be a checklist on file for the most current version of the electronic information system used within the Clinical Trials Networks.
- When completing this checklist, information should be entered in each field that contains blue text prompts, and each Yes, No, or N/A checkbox should be clicked as appropriate to answer each question.
- A mitigation risk must be entered in the Risk Mitigation box for each line item marked as No. Enter N/A in this box for each section where a risk mitigation or additional supporting comment is not applicable.
- NOTE: Completion of and compliance with this checklist does not replace the requirement for each site/organization to have documented evidence of system validation on file and available for inspection if necessary. It is expected that the documented evidence of system validation confirms 21 CFR Part 11 compliance attested to in this checklist.

National Institute of Allergy and Infectious Diseases	Document Number: DAIDS-OPC-A15-GUD- 00006	Revision Number: 02
Division of AIDS	Effective Date: 29 May 2024	Page: 2 of 14
Document Title: Appendix B Electronic Information System Evaluation	on Checklist	

		System Evaluation Checklist
	S	Site Information
Date of Submission:		
Site Number (if applicable):	
Site/Organization Name:		
Site/Organization Contact	Name:	
Site/Organization Contact	Phone:	
Site/Organization Contact	Email:	
	•	
	Sys	stem Information
lame of System being Asso	ssed:	
System Version #:		Date of Implementation:
Describe the <i>purpose</i> of		
he system:		
Dosoviho the munes		
Describe the <i>process</i> surrounding the use of		
he system:		
		Software Acquisition:
/endor Name:		☐ Purchased Software (Run/Installed locally)
		☐ In-House/Custom Developed Software
ystem Contact Person:		☐ Software as a Service (SaaS)
Other Information:		
Other Information:		

National Institute of Allergy and Infectious Diseases	Document Number: DAIDS-OPC-A15-GUD- 00006	Revision Number: 02
Division of AIDS	Effective Date: 29 May 2024	Page: 3 of 14
Document Title: Appendix B Electronic Information System Evaluation	on Checklist	

Determining System Applicability

- Utilize Section 1.0 to determine if the electronic information system being used within the Clinical Trials Networks falls within the scope of this checklist as stated in the Instructions section.
- If **ANY** of the questions in Section 1.0 are answered **Yes**, the system falls within scope and the checklist <u>must be</u> <u>completed</u>. Proceed to the Section 2.0.
- If **ALL** the questions in Section 1.0 are answered **No**, the system does not fall within scope and the checklist <u>does not</u> <u>need to be completed</u>. Proceed to the **Review Acknowledgement** section.

Secti	Section 1.0 EIS Evaluation Checklist Scope Determination			
1.1	Does the system generate, capture, process, report, store, or archive raw and/or source data or records?	☐ Yes ☐ No		
1.2	Will the data or records from this system be submitted as part of required periodic (e.g., annual) study reports?	☐ Yes ☐ No		
1.3	Will the data or records from this system be part of a final clinical study report (CSR)?	□ Yes □ No		
1.4	Would the data or records, such as essential documents, from this system be required to reconstruct a trial?	☐ Yes ☐ No		
1.5	Could participant safety be impacted from decisions made using incorrect or inaccurate data or records from this system?	☐ Yes ☐ No		
1.6	Could participant safety be impacted from other systems processing incorrect or inaccurate data or records from this system?	☐ Yes ☐ No		
<u>All</u> questions answered No : Proceed to <u>Review Acknowledgement</u> section at the end of the document. <u>Any</u> questions answered Yes : Proceed to <u>Section 2.0 Validation</u> .				

National Institute of Allergy and Infectious Diseases	Document Number: DAIDS-OPC-A15-GUD- 00006	Revision Number: 02
Division of AIDS	Effective Date: 29 May 2024	Page: 4 of 14
Document Title: Appendix B Electronic Information System Evaluation	on Checklist	

Electronic Records Requirements

		<u> </u>		
Secti	ion 2.0 Validation			
2.1	Has this system been validated by your office according to in-house computer system validation procedures?	□ Yes	□ No	□ N/A
2.2	If the system has been validated by your office, is the validation documentation available for review, if required, during a regulatory inspection?	□ Yes	□ No	□ N/A
2.3	Has the vendor validated the system according to the vendor's computer system validation procedures?	□ Yes	□ No	□ N/A
2.4	If the vendor has validated the system, can they provide you with a validation certificate or a similar documentation?	□ Yes	□ No	□ N/A
2.5	If the vendor has validated the system, will they make the validation documentation available for review, if required, during a regulatory inspection?	□ Yes	□ No	□ N/A
docur	: If any of the answers above are "No", consider what mitigations of this risk are possible. Con mented testing with objective evidence to prove at a minimum the functions being used to su orking accurately and consistently.			
Risk I	Risk Mitigations/Comments:			
Sacti	Section 3.0 Electronic Records Controls			
Section				
3.1	Is the system able to produce accurate and complete copies of the data/records contained within the system (e.g., on paper)?	□ Yes	□No	□ N/A
3.2	Is the system able to provide the information in an electronic format (e.g., Excel file, .csv, .xml or similar data extract)?	□ Yes	□ No	□ N/A
3.3	Is the necessary equipment available to place the electronic data/records on an encrypted universal serial bus (USB) drive or other media if required by the regulatory authority?	□Yes	□ No	□ N/A
Note	Note: If any of the answers above are "No", consider what mitigations of this risk are possible.			
Risk I	Risk Mitigations/Comments:			

National Institute of Allergy and Infectious Diseases	Document Number: DAIDS-OPC-A15-GUD- 00006	Revision Number: 02
Division of AIDS	Effective Date: 29 May 2024	Page: 5 of 14
Document Title: Appendix B Electronic Information System Evaluati	on Checklist	

Section	Section 4.0 Protection of Records (applicable for locally run/installed and SaaS systems)					
4.1	Are the data/records readily retrievable throughout the retention period?	□ Yes	□No	□ N/A		
4.2	Are the data/records backed up regularly and maintained in a separate location (e.g., alternate clinical site, another location, cloud storage) for disaster recovery purposes?	□ Yes	□No	□ N/A		
4.3	Is a disaster mitigation and recovery plan in place and regularly reviewed?	□ Yes	□ No	□ N/A		
4.4	Are the data/records protected using a firewall?	□ Yes	□No	□ N/A		
4.5	Have firewall rules been defined by the site/organization?	□ Yes	□ No	□ N/A		
4.6	Are firewall rules and setting periodically reviewed?	□ Yes	□No	□ N/A		
4.7	Is anti-virus software installed to prevent, detect, and mitigate the effects of viruses, malware, and other harmful software?	□ Yes	□No	□ N/A		
4.8	Is the anti-virus software continuously monitored and updated with the most recent virus definitions?	□ Yes	□No	□ N/A		
4.9	Are relevant security patches for platforms and operating systems applied in a timely manner according to vendor recommendations?	□ Yes	□No	□ N/A		
4.10	Is penetration testing conducted at regular intervals for internet facing systems?	□ Yes	□No	□ N/A		
4.11	Has an intrusion detection and prevention system been implemented on internet facing systems?	□ Yes	□No	□ N/A		
4.12	Have security incident management procedures been defined including reporting, criticality assignment, and corrective and preventive action implementation?	□ Yes	□No	□ N/A		
4.13	Have interfaces between systems (e.g., transfer of data from one system to another) been clearly defined and validated?	□ Yes	□No	□ N/A		
Note: If any of the answers above are "No", consider what mitigations of this risk are possible. Consider when/if keeping paper records might be necessary if systems are not adequately protected. Add a strong virus protection software to the computer system if possible. Ensure information is available to reconstruct source documentation for regulatory inspection and be prepared to describe how data was obtained and managed to prove the integrity of the data. Document changes made to any systems and carefully evaluate the effects of those changes. Risk Mitigations/Comments:						

National Institute of Allergy and Infectious Diseases	Document Number: DAIDS-OPC-A15-GUD- 00006	Revision Number: 02		
Division of AIDS	Effective Date: 29 May 2024	Page: 6 of 14		
Document Title: Appendix B Electronic Information System Evaluation Checklist				

Section	on 5.0 Access Control of Records			
5.1	Does the system ensure that only authorized individuals can use it, electronically sign records, alter records, or perform other operations as required?	□ Yes	□No	□ N/A
5.2	Does the system prompt for an individual's login account and password to prevent unauthorized users from accessing data/records?	□ Yes	□No	□ N/A
5.3	Are controls in place to maintain the uniqueness of the user ID and password so that no individual can have the same combination?	□ Yes	□No	□ N/A
5.4	Is a process in place to promptly remove access upon the departure of an internal employee or upon notification of staff departures from external entities/users?	□ Yes	□No	□ N/A
5.5	Are requests for access approved and documented?	□ Yes	□No	□ N/A
5.6	Are users granted the fewest privileges and access rights (least-privilege rule) for them to undertake their specific job duties for as short a time as necessary?	□ Yes	□No	□ N/A
5.7	Are user accounts traceable to a named user (e.g., no generic or shared accounts)?	□ Yes	□No	□ N/A
5.8	Are periodic user access and privilege review procedures in place that include but are not necessarily limited to ensuring only necessary and approved users have access, their roles and permissions are appropriate, and their access is promptly removed when no longer necessary or permitted?	□Yes	□No	□ N/A
5.9	Are processes in place to deactivate lost, stolen, missing or otherwise compromised IDs, tokens, cards, etc. that are used for access and/or electronic signature purposes?	□ Yes	□No	□ N/A
5.10	Are processes in place for initial and periodic testing of IDs, tokens, cards, etc. that are used for access and/or electronic signature purposes?	□ Yes	□No	□ N/A
5.11	Is there a process to ensure the recalling of IDs, tokens, cards, etc. if a person leaves employment or is transferred to a different job role?	□ Yes	□No	□ N/A
5.12	Does the system have safeguards to prevent unauthorized use of passwords and/or identification codes?	□ Yes	□No	□ N/A
5.13	Is there a process in place to immediately detect and report attempts at unauthorized use of passwords and/or identification codes?	□ Yes	□No	□ N/A
5.14	Have password policies been implemented that include but are not necessarily limited to, length, complexity, expiry, login attempts, and logout reset?	□ Yes	□No	□ N/A
5.15	Have the password policies been verified and documented as part of the system validation?	□ Yes	□No	□ N/A
5.16	Are individual accounts password protected?	□ Yes	□No	□ N/A
5.17	Are passwords required to be reset at some set periodic interval?	□ Yes	□ No	□ N/A

National Institute of Allergy and Infectious Diseases	Document Number: DAIDS-OPC-A15-GUD- 00006	Revision Number: 02		
Division of AIDS	Effective Date: 29 May 2024	Page: 7 of 14		
Document Title: Appendix B Electronic Information System Evaluation Checklist				

Section	on 5.0 Access Control of Records			
5.18	Is the system setup with an automatic inactivity logout to log out users after a defined period of inactivity?	□ Yes	□No	□ N/A
5.19	Is the system setup to prevent the average user from setting the inactivity timeframe or deactivating the functionality?	□ Yes	□No	□ N/A
5.20	Does the system limit the number of failed login attempts?	□ Yes	□No	□ N/A
5.21	Is the system available with full, direct, and read-only access (this requires a unique identification method e.g., username and password) upon request by inspectors from regulatory authorities?	□ Yes	□ No	□ N/A
Note: If any of the answers above are "No", consider what mitigations of this risk are possible. Implementing a procedure that is followed to onboard or offboard and employee is one way to mitigate risks regarding control of access. A procedure to train individuals on protecting their accounts is also recommended to include: 1. Do not share individual account access with other users, 2. Do not log on to a system to provide access for another user, 3. Require users to change passwords at regular intervals, and 4. Automatically lock computers when left idle for a short period of time.				
Risk Mitigations/Comments:				

Section	on 6.0 Audit Trails	
6.1	Does the system have an audit trail to track user entries and actions that create, modify, or delete data/records? <i>Note: if answered No or N/A, all other answers in this section will be N/A.</i>	☐ Yes ☐ No ☐ N/A
6.2	Does the audit trail keep copies of deleted records?	□ Yes □ No □ N/A
6.3	Does the audit trail ensure that the previously recorded information is still available (i.e., not obscured by the change)?	□ Yes □ No □ N/A
6.4	Does the audit trail contain a timestamp that is applied automatically?	□ Yes □ No □ N/A
6.5	Does the audit trail track changes in a consistent time zone (e.g., Coordinated Universal Time (UTC))?	□ Yes □ No □ N/A
6.6	Does the audit trail keep track of the individual user, including system administrators, who made the change?	□ Yes □ No □ N/A
6.7	Is the audit trail protected from modification and deletion by any user, including system administrators?	□ Yes □ No □ N/A
6.8	Is it possible to discern invalid or altered records?	☐ Yes ☐ No ☐ N/A

National Institute of Allergy and Infectious Diseases	Document Number: DAIDS-OPC-A15-GUD- 00006	Revision Number: 02			
Division of AIDS	Effective Date: 29 May 2024	Page: 8 of 14			
Document Title: Appendix B Electronic Information System Evaluation Checklist					

Section	on 6.0 Audit Trails			
6.9	Is the audit trail available for review throughout the data/record's retention period?	☐ Yes ☐ No ☐ N/A		
6.10	Is the audit trail stored within the system itself?	☐ Yes ☐ No ☐ N/A		
6.11	Is the audit trail in human-readable format that is comprehendible?	☐ Yes ☐ No ☐ N/A		
6.12	Is the audit trail visible at the data-point level in the live system?	□Yes □No □N/A		
6.13	Is it possible to export the entire audit trail as a dynamic data file (e.g., into an Excel workbook versus as a PDF)?	☐ Yes ☐ No ☐ N/A		
6.14	Have audit trail review procedures been put in place that include documentation of the reviews?	☐ Yes ☐ No ☐ N/A		
Note: If any of the answers above are "No", consider what mitigations of this risk are possible. For an audit trail to be compliant it must meet all the above criteria. Consider a change log with needed details if components of the above audit trail requirements are missing.				
Risk Mitigations/Comments:				

Secti	on 7.0 Operational Checks			
7.1	Is the computer system date and time synchronized to an international standard setting source (e.g., UTC)?	□ Yes	□ No	□ N/A
7.2	Does the system limit a user's ability to change date or time?	□ Yes	□ No	□ N/A
7.3	Does the system include year, month, day, hour, minute, and time zone in time stamps?	□ Yes	□ No	□ N/A
7.4	Does the system have checks to ensure steps are performed in the correct order if the sequence of system steps or events is important?	□ Yes	□ No	□ N/A
7.5	Does the system contain checks to identify invalid values and alert the user?	□ Yes	□ No	□ N/A
7.6	Does the system prevent default data entries or automatic duplication of data? (N/A if system is programmed to do so)	☐ Yes	□ No	□ N/A

Note: If any of the answers above are "No", consider what mitigations of this risk are possible. Procedures to ensure users know the order of tasks can help mitigate risks regarding this requirement. Consideration may also be given to documenting all date and time changes made to the computer including when changes are made for daylight savings time. Also consider documenting time zone references and naming conventions in the study and validation documentation.

NII	National Institute of Allergy and Infectious Diseases	DAIDS-OPC-A15-GUD-	Revision Number: 02		:
Divis	ion of AIDS		Page: 9 of 14		
Docu	ument Title: Appendix B Electronic Information System Evaluation	on Checklist			
Section	on 7.0 Operational Checks				
Risk N	Aitigations/Comments:				
Section	on 8.0 Device Checks				
8.1	Does the system track which device or piece of equipment was (e.g., vital sign, ECG)? This applies only when more than one de	-	☐ Yes	□No	□ N/A
	If the answer above is "No", consider what mitigations of this risment on the record or some type of log.	sk are possible. Consider red	ording th	nis inforr	mation in
Risk N	Aitigations/Comments:				
Section	on 9.0 Training				
9.1	Do the individuals that develop, maintain, and/or use the system training, and experience to perform their assigned tasks?	m have sufficient education	,	□ Yes	□ No
9.2	Is system training documented?			☐ Yes	□ No
	If any of the answers above are "No", consider what mitigations	•		•	
•	tion and use of the system and document that the training occur ersonnel are adequately trained as they come on board.	rred. Conduct training session	ons as ne	eded to	ensure
KISK IV	Aitigations/Comments:				
Section	on 10.0 System Documentation				
10.1	Is the distribution of, access to, and the use of systems operation documentation controlled?	on and maintenance	☐ Yes	□No	□ N/A
10.2	Are there revision and change control procedures established to that documents time-sequenced development and modification documentation?	-	□ Yes	□ No	□ N/A
10.3	Have procedures been put in place to ensure that the compute correctly?	rized system is used	☐ Yes	□No	□ N/A
Note:	If any of the answers above are "No", consider what mitigations	of this risk are possible. En	sure doci	umentat	ion

contains a revision history to identify changes made and keep copies of all published versions of the documentation.

NII	National Institute of Allergy and Infectious Diseases	DAIDS-OPC-A15-GUD-	Revision Number:			
Divis	Division of AIDS Effective Date: Page: 10 of 14					
Docu	ment Title: Appendix B Electronic Information System Evaluation	on Checklist				
Section	on 10.0 System Documentation					
Risk M	litigations/Comments:					
Section	on 11.0 Controls for Open Systems					
Section	III.0 Controls for Open Systems					
11.1	Are the data (at rest) encrypted on the storage device?		☐ Yes ☐ No ☐ N/A			
11.2	.2 Are the data (in motion) encrypted throughout the process of managing and/or transmitting the data?					
Note:	If any of the answers above are "No", consider what mitigations	of this risk are possible.				
Risk N	litigations/Comments:					
Section	on 12.0 Electronic Signature Policy					
12.1	12.1 Is there a formal policy for internal systems that ensures individuals are held fully accountable and responsible for actions initiated under their electronic signatures?					
	If the answer above is "No", consider what mitigations of this risage to your onboarding documents that must be accepted by the	•	iting a policy or adding			
Risk N	Aitigations/Comments:					

National Institute of Allergy and Infectious Diseases	Document Number: DAIDS-OPC-A15-GUD- 00006	Revision Number: 02				
Division of AIDS	Effective Date: 29 May 2024	Page: 11 of 14				
Document Title: Appendix B Electronic Information System Evaluation Checklist						

Question answered No: Proceed to Review Acknowledgement section at the end of the document. Question answered Yes: Proceed to Section 14.0 Electronic Signature Certification. Section 14.0 Electronic Signature Certification (for internal staff users only) 14.1 Have plans been submitted in writing to use electronic signature to the FDA?	Document Title: Appendix B Electronic Information System Evaluation Checklist					
Section 13.0 Electronic Signature Determination 13.1 Does the system use electronic signatures? Question answered No: Proceed to Review Acknowledgement section at the end of the document. Question answered Yes: Proceed to Section 14.0 Electronic Signature Certification. Section 14.0 Electronic Signature Certification (for internal staff users only) 14.1 Have plans been submitted in writing to use electronic signature to the FDA? Note: If the answer above is "No", consider what mitigations of this risk are possible. Consider submitting the non-repudiation agreement by using the sample letters provided by the FDA. The Letter of Non-Repudiation Agreement can be sent to ESG Help Desk at ESGHelpDesk@fda.hhs.gov or a physical copy can be sent to: Electronic Submissions Gateway U.S. Food and Drug Administration 3WFN, Room 7C34 12225 Wilkins Avenue Rockville, MD 20852 Risk Mitigations/Comments: Section 15.0 Identity Verification 15.1 Is there a process in place to verify the identity of the individual before providing them the ability by to sign electronically? Note: If the answer above is "No", consider what mitigations of this risk are possible. Establish a process for verifying identity and consider including this process in the account management policy/procedure.						
Question answered No: Proceed to Review Acknowledgement section at the end of the document. Question answered Yes: Proceed to Section 14.0 Electronic Signature Certification. Section 14.0 Electronic Signature Certification (for internal staff users only) 14.1 Have plans been submitted in writing to use electronic signature to the FDA? Note: If the answer above is "No", consider what mitigations of this risk are possible. Consider submitting the non-repudiation agreement by using the sample letters provided by the FDA. The Letter of Non-Repudiation Agreement can be sent to ESG Help Desk at ESGHelpDesk@fda.hhs.gov or a physical copy can be sent to: Electronic Submissions Gateway U.S. Food and Drug Administration 3WFN, Room 7C34 12225 Wilkins Avenue Rockville, MD 20852 Risk Mitigations/Comments: Section 15.0 Identity Verification 15.1 Is there a process in place to verify the identity of the individual before providing them the ability to sign electronically? Note: If the answer above is "No", consider what mitigations of this risk are possible. Establish a process for verifying identity and consider including this process in the account management policy/procedure.		Electronic Signature Requirements				
Question answered No: Proceed to Review Acknowledgement section at the end of the document. Question answered Yes: Proceed to Section 14.0 Electronic Signature Certification. Section 14.0 Electronic Signature Certification (for internal staff users only) 14.1 Have plans been submitted in writing to use electronic signature to the FDA? Note: If the answer above is "No", consider what mitigations of this risk are possible. Consider submitting the non-repudiation agreement by using the sample letters provided by the FDA. The Letter of Non-Repudiation Agreement can be sent to ESG Help Desk at ESGHelpDesk@fda.hhs.gov or a physical copy can be sent to: Electronic Submissions Gateway U.S. Food and Drug Administration 3WFN, Room 7C34 12225 Wilkins Avenue Rockville, MD 20852 Risk Mitigations/Comments: Section 15.0 Identity Verification 15.1 Is there a process in place to verify the identity of the individual before providing them the ability to sign electronically? Note: If the answer above is "No", consider what mitigations of this risk are possible. Establish a process for verifying identity and consider including this process in the account management policy/procedure.						
Question answered No: Proceed to Review Acknowledgement section at the end of the document. Question answered Yes: Proceed to Section 14.0 Electronic Signature Certification. Section 14.0 Electronic Signature Certification (for internal staff users only) 14.1 Have plans been submitted in writing to use electronic signature to the FDA? Yes No Note: If the answer above is "No", consider what mitigations of this risk are possible. Consider submitting the non-repudiation agreement by using the sample letters provided by the FDA. The Letter of Non-Repudiation Agreement can be sent to ESG Help Desk at ESGHelpDesk@fda.hhs.gov or a physical copy can be sent to: Electronic Submissions Gateway U.S. Food and Drug Administration 3WFN, Room 7C34 12225 Wilkins Avenue Rockville, MD 20852 Risk Mitigations/Comments: Section 15.0 Identity Verification 15.1 Is there a process in place to verify the identity of the individual before providing them the ability to sign electronically? Yes No Note: If the answer above is "No", consider what mitigations of this risk are possible. Establish a process for verifying identity and consider including this process in the account management policy/procedure.	Section	n 13.0 Electronic Signature Determination				
Section 14.0 Electronic Signature Certification (for internal staff users only) 14.1 Have plans been submitted in writing to use electronic signature to the FDA?	13.1	Does the system use electronic signatures?	☐ Yes ☐ No			
14.1 Have plans been submitted in writing to use electronic signature to the FDA? Yes Note: If the answer above is "No", consider what mitigations of this risk are possible. Consider submitting the non-repudiation agreement by using the sample letters provided by the FDA. The Letter of Non-Repudiation Agreement can be sent to ESG Help Desk at ESGHelpDesk@fda.hhs.gov or a physical copy can be sent to: Electronic Submissions Gateway U.S. Food and Drug Administration 3WFN, Room 7C34 12225 Wilkins Avenue Rockville, MD 20852 **Risk Mitigations/Comments:** Section 15.0 Identity Verification 15.1 Is there a process in place to verify the identity of the individual before providing them the ability to sign electronically? **Note:* If the answer above is "No", consider what mitigations of this risk are possible. Establish a process for verifying identity and consider including this process in the account management policy/procedure.						
Note: If the answer above is "No", consider what mitigations of this risk are possible. Consider submitting the non-repudiation agreement by using the sample letters provided by the FDA. The Letter of Non-Repudiation Agreement can be sent to ESG Help Desk at ESGHelpDesk@fda.hhs.gov or a physical copy can be sent to: Electronic Submissions Gateway U.S. Food and Drug Administration 3WFN, Room 7C34 12225 Wilkins Avenue Rockville, MD 20852 Risk Mitigations/Comments: Section 15.0 Identity Verification 15.1 Is there a process in place to verify the identity of the individual before providing them the ability to sign electronically? Note: If the answer above is "No", consider what mitigations of this risk are possible. Establish a process for verifying identity and consider including this process in the account management policy/procedure.	Sectio	n 14.0 Electronic Signature Certification (for internal staff users only)				
repudiation agreement by using the sample letters provided by the FDA. The Letter of Non-Repudiation Agreement can be sent to ESG Help Desk at ESGHelpDesk@fda.hhs.gov or a physical copy can be sent to: Electronic Submissions Gateway U.S. Food and Drug Administration 3WFN, Room 7C34 12225 Wilkins Avenue Rockville, MD 20852 Risk Mitigations/Comments: Section 15.0 Identity Verification 15.1 Is there a process in place to verify the identity of the individual before providing them the ability to sign electronically? Note: If the answer above is "No", consider what mitigations of this risk are possible. Establish a process for verifying identity and consider including this process in the account management policy/procedure.	14.1	Have plans been submitted in writing to use electronic signature to the FDA?	□ Yes □ No			
can be sent to: Electronic Submissions Gateway U.S. Food and Drug Administration 3WFN, Room 7C34 12225 Wilkins Avenue Rockville, MD 20852 Risk Mitigations/Comments: Section 15.0 Identity Verification 15.1 Is there a process in place to verify the identity of the individual before providing them the ability to sign electronically? Note: If the answer above is "No", consider what mitigations of this risk are possible. Establish a process for verifying identity and consider including this process in the account management policy/procedure.	repudi	ation agreement by using the sample letters provided by the FDA.				
U.S. Food and Drug Administration 3WFN, Room 7C34 12225 Wilkins Avenue Rockville, MD 20852 Risk Mitigations/Comments: Section 15.0 Identity Verification 15.1 Is there a process in place to verify the identity of the individual before providing them the ability to sign electronically? Note: If the answer above is "No", consider what mitigations of this risk are possible. Establish a process for verifying identity and consider including this process in the account management policy/procedure.	can be	sent to:	mysical copy			
3WFN, Room 7C34 12225 Wilkins Avenue Rockville, MD 20852 Risk Mitigations/Comments: Section 15.0 Identity Verification 15.1 Is there a process in place to verify the identity of the individual before providing them the ability to sign electronically? Note: If the answer above is "No", consider what mitigations of this risk are possible. Establish a process for verifying identity and consider including this process in the account management policy/procedure.		·				
Risk Mitigations/Comments: Section 15.0 Identity Verification 15.1 Is there a process in place to verify the identity of the individual before providing them the ability to sign electronically? Note: If the answer above is "No", consider what mitigations of this risk are possible. Establish a process for verifying identity and consider including this process in the account management policy/procedure.						
Section 15.0 Identity Verification 15.1 Is there a process in place to verify the identity of the individual before providing them the ability to sign electronically? □ Yes □ Note: If the answer above is "No", consider what mitigations of this risk are possible. Establish a process for verifying identity and consider including this process in the account management policy/procedure.						
Section 15.0 Identity Verification 15.1 Is there a process in place to verify the identity of the individual before providing them the ability to sign electronically? Note: If the answer above is "No", consider what mitigations of this risk are possible. Establish a process for verifying identity and consider including this process in the account management policy/procedure.						
15.1 Is there a process in place to verify the identity of the individual before providing them the ability to sign electronically? Note: If the answer above is "No", consider what mitigations of this risk are possible. Establish a process for verifying identity and consider including this process in the account management policy/procedure.	Risk M	itigations/Comments:				
15.1 Is there a process in place to verify the identity of the individual before providing them the ability to sign electronically? Note: If the answer above is "No", consider what mitigations of this risk are possible. Establish a process for verifying identity and consider including this process in the account management policy/procedure.						
15.1 Is there a process in place to verify the identity of the individual before providing them the ability to sign electronically? Note: If the answer above is "No", consider what mitigations of this risk are possible. Establish a process for verifying identity and consider including this process in the account management policy/procedure.	Section	n 15 0 Identity Verification				
to sign electronically? Note: If the answer above is "No", consider what mitigations of this risk are possible. Establish a process for verifying identity and consider including this process in the account management policy/procedure.	Jectio					
identity and consider including this process in the account management policy/procedure.	15.1	, , , , , , , , , , , , , , , , , , , ,	☐ Yes ☐ No			
2.1.4.2	· · · · · · · · · · · · · · · · · · ·					
Risk Mitigations/Comments:	Risk M	itigations/Comments:				

NIF	National Institute of Allergy and Infectious Diseases	Document Number: DAIDS-OPC-A15-GUD-00006	Revision N 02	umber:	
Division of AIDS Effective Date: Page: 12 of 14					
Document Title: Appendix B Electronic Information System Evaluation Checklist					
Sectio	n 16.0 Electronic Signature Uniqueness				
16.1	Are electronic signatures unique to an individual?			□ Yes	□No
16.2	Is there a process in place to ensure electronic signatures are ranyone else?	never reused by or reassigr	ned to	□ Yes	□No
manag is rehir	f any of the answers above are "No", consider what mitigations ement policy or procedure to ensure user identifications (IDs) a ed that they should receive the same user ID assigned previous ectronic signature representation.	re not reused and consider	r including t	that if a _l	person
Risk Mitigations/Comments:					
Section 17.0 Electronic Signature Components					
17.1	Does the signature require the use of at least two components ID card and pin number)?	s (i.e., a user ID and passwo	ord or an	□ Yes	□No
17.2	Does the system prompt for a re-entry of the password or pin upon each application of the electronic signature?			□ Yes	□No
17.3	Does the system prompt for both components (i.e., a user ID and password or an ID card and pin			□ Yes	□No
17.4	Is there a process in place to ensure electronic signatures are of	only used by their genuine	owners?	□ Yes	□No
17.5	Are electronic signatures administered and executed in a way that requires collaboration of at least two individuals if an attempt is made to falsify a signature?			□ Yes	□No
Note: If any of the answers above are "No", consider what mitigations of this risk are possible. Consider a policy that assures user IDs and passwords are not shared and that users properly log out upon completion of their work particularly if they are using shared workstations.					
Risk Mitigations/Comments:					
Sactio	n 18.0 Electronic Signature Elements				
Jectio	11 10.0 Liettionic Signature Lienients				
18.1	Does the signed electronic record contain the printed name of	the signer?		☐ Yes	□ No

NII	National Institute of Allergy and Infectious Diseases Document Number: DAIDS-OPC-A15-GUD- 00006 Revision Number: 02					
Divis	Division of AIDS Effective Date: Page: 13 of 14					
Document Title: Appendix B Electronic Information System Evaluation Checklist						
Section	on 18.0 Electronic Signature Elements					
18.2	Does the signed electronic record contain the date and time c (e.g., UTC)?	f the signing (including time	e zone)	□ Yes	□No	
18.3	Does the signed electronic record contain the meaning of the approval, review)?	signature that was applied	(e.g.,	☐ Yes	□No	
18.4	Is the electronic signature and all three (3) of its components time of signing, and meaning of signature) available for viewir shown in human readable format (e.g., on an electronic displa	ng when the electronic reco		□ Yes	□No	
Note:	If any of the answers above are "No", consider what mitigation	s of this risk are possible.				
Risk N	litigations/Comments:					
Section	n 19.0 Electronic Signature Linking					
19.1	Are the electronic signatures linked to their respective electron the signatures cannot be removed, copied, cut and pasted, or the means in order to falsify an alternate electronic record?		☐ Yes	□No		
	Are handwritten signatures applied to electronic records linked in a manner that ensures			□ 140		
19.2	that the signature cannot be removed, copied, or transferred t				□ N/A	
	that the signature cannot be removed, copied, or transferred t	o falsify an alternate			□ N/A	
Note:	that the signature cannot be removed, copied, or transferred t electronic record?	o falsify an alternate			□ N/A	
Note:	that the signature cannot be removed, copied, or transferred t electronic record? If any of the answers above are "No", consider what mitigation	o falsify an alternate			□ N/A	
Note:	that the signature cannot be removed, copied, or transferred t electronic record? If any of the answers above are "No", consider what mitigation	o falsify an alternate			□ N/A	
Note: Risk N	that the signature cannot be removed, copied, or transferred t electronic record? If any of the answers above are "No", consider what mitigation	o falsify an alternate			□ N/A	
Note: Risk N	that the signature cannot be removed, copied, or transferred to electronic record? If any of the answers above are "No", consider what mitigation altigations/Comments:	o falsify an alternate	□Yes	□No	□ N/A □ N/A	
Note: Risk N Section 20.1 Note:	that the signature cannot be removed, copied, or transferred to electronic record? If any of the answers above are "No", consider what mitigations dittigations/Comments: In 20.0 Biometric Electronic Signatures Is there a process in place to ensure that electronic signatures	o falsify an alternate s of this risk are possible. based on biometrics can sk are possible. Ensure any	□Yes	□ No	□ N/A	

National Institute of Allergy and Infectious Diseases	Document Number: DAIDS-OPC-A15-GUD- 00006	Revision Number: 02		
Division of AIDS	Effective Date: 29 May 2024	Page: 14 of 14		
Document Title: Appendix B Electronic Information System Evaluation Checklist				

Review Acknowledgement

Note: When applying signatures, both signature and date should be in the same format (e.g., handwritten signature and handwritten date or signature and date included as part of a digital/electronic signature).

Section 21.0 Assessor Acknowledgement	
By signing this document, you indicate that the information contained within this document is accurate and complete to the best of your knowledge.	
	Signature and Date:
Printed Name:	
Title:	
Section 22.0 CRS Leader, DMC Director, or Entity Leader/Director (as applicable)	
By signing this document, you indicate that you have reviewed and approve the information contained within this document.	
	Signature and Date:
Printed Name:	
Title:	

REVISION HISTORY

- 1. APP-A15-OPC-006.00 is the original version of this Appendix.
- 2. DAIDS-OPC-A15-GUD-00006 rev 01 is the first revision of this Appendix in MasterControl. The document format and numbering were updated to reflect the current QMS (Master Control) requirements.
- 3. DAIDS-OPC-A15-GUD-00006 rev 02 Overall document was updated to provide additional clarity to users. System Applicability section was added to assist users in determining if the system in question falls within the scope of the checklist. Document was updated throughout to align with new EMA Guideline on computerised systems and electronic data in clinical trials, 2023.